Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.

ABSTRACT: Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia and eosinophil-related clinical manifestations. Although the recent availability of biologic therapies that directly and indirectly target eosinophils has the potential to dramatically improve treatment options for all EADs, clinical trials addressing their safety and efficacy in rare EADs have been relatively few. Consequently, patient access to therapy is limited for many biologics, and the establishment of evidence-based treatment guidelines has been extremely difficult. In this regard, multicenter retrospective collabora

SUBMITTER: Khoury P 

PROVIDER: S-EPMC11271980 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature